We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+37.6%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$232M
AUM Growth
+$52.7M
Cap. Flow
+$13.9M
Cap. Flow %
6%
Top 10 Hldgs %
61.94%
Holding
59
New
16
Increased
15
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
BLU
BELLUS Health Inc.
BLU
+$6.62M
2
WHWK
Whitehawk Therapeutics
WHWK
+$4.21M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.18M
4
BCAB icon
BioAtla
BCAB
+$3.4M
5
UTHR icon
United Therapeutics
UTHR
+$3.24M

Top Sells

Rank Stock Value
1
VTGN icon
VistaGen Therapeutics
VTGN
+$10M
2
RCUS icon
Arcus Biosciences
RCUS
+$4.24M
3
OBIO icon
Orchestra BioMed
OBIO
+$3.91M
4
DTIL icon
Precision BioSciences
DTIL
+$3.28M
5
MRUS
Merus
MRUS
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 90.75%
2 Financials 6.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TERN
26
DELISTED
Terns Pharmaceuticals
TERN
$2.07M 0.89%
+350,702
New +$1.3M
PCVX icon
27
Vaxcyte
PCVX
$8.5B
$2.04M 0.88%
+85,000
New +$2.15M
PMVP icon
28
PMV Pharmaceuticals
PMVP
$62.9M
$1.84M 0.79%
154,500
+2,000
+1% +$28.9K
FULC icon
29
Fulcrum Therapeutics
FULC
$288M
$1.78M 0.77%
220,000
+20,000
+10% +$143K
ALT icon
30
Altimmune
ALT
$585M
$1.6M 0.69%
+125,000
New +$1.85M
IOVA icon
31
Iovance Biotherapeutics
IOVA
$2.77B
$1.47M 0.63%
153,639
-717
-0.5% -$8.27K
PYXS icon
32
Pyxis Oncology
PYXS
$238M
$1.32M 0.57%
669,158
+24,009
+4% +$62.7K
MRUS
33
DELISTED
Merus
MRUS
$1.18M 0.51%
59,000
-95,000
-62% -$2.27M
ALLK
34
DELISTED
Allakos
ALLK
$1.18M 0.51%
+192,500
New +$806K
RZLT icon
35
Rezolute
RZLT
$453M
$1.15M 0.49%
419,145
-225,991
-35% -$653K
IMGN
36
DELISTED
Immunogen Inc
IMGN
$669K 0.29%
+140,000
New +$738K
HZNP
37
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$248K 0.11%
4,000
-31,888
-89% -$2.23M
ESPR
38
DELISTED
Esperion Therapeutics
ESPR
$201K 0.09%
+30,000
New +$206K
IDYA icon
39
IDEAYA Biosciences
IDYA
$3.49B
$149K 0.06%
+10,000
New +$130K
SWTX
40
DELISTED
SpringWorks Therapeutics
SWTX
$143K 0.06%
5,000
– –
DICE
41
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$136K 0.06%
+6,700
New +$122K
ZNTL icon
42
Zentalis Pharmaceuticals
ZNTL
$356M
$108K 0.05%
+5,000
New +$137K
NGM
43
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$98K 0.04%
+7,500
New +$114K
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$60K 0.03%
+5,000
New +$65.4K
TRVI icon
45
Trevi Therapeutics
TRVI
$2.63B
$56K 0.02%
36,302
+1,302
+4% +$4.27K
NUVB.WS
46
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$15K 0.01%
90,832
– –
BMEA icon
47
Biomea Fusion
BMEA
$90.4M
$10K ﹤0.01%
+1,000
New +$11.5K
ACAD icon
48
Acadia Pharmaceuticals
ACAD
$4.9B
– –
-71,500
Closed -$1.01M
DTIL icon
49
Precision BioSciences
DTIL
$191M
– –
-68,345
Closed -$3.28M
ENTA icon
50
Enanta Pharmaceuticals
ENTA
$388M
– –
-27,500
Closed -$1.3M
1
2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return

Acuta Capital Partners's Q3 2022 Portfolio in Review

As of Q3 2022, Acuta Capital Partners held 59 positions worth $232M, up 29% from $179M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Acuta Capital Partners deployed $13.9M of net new capital in Q3 2022, opening 16 new positions and adding to 15 existing holdings. Its largest new stake was Sarepta Therapeutics: 41,500 shares worth $4.59M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 89% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Merus, an estimated $2.27M trimmed.

  • Acuta Capital Partners's largest Q3 2022 buy was Sarepta Therapeutics: 41,500 shares worth $4.59M.
  • Acuta Capital Partners added most to BELLUS Health Inc. in Q3 2022, an estimated $6.62M increase.
  • Acuta Capital Partners's biggest Q3 2022 reduction was Merus, cutting an estimated $2.27M.
  • Acuta Capital Partners fully exited VistaGen Therapeutics in Q3 2022, selling an estimated $10M.
  • Acuta Capital Partners's ten largest holdings make up 62% of its $232M portfolio in Q3 2022.
  • Acuta Capital Partners opened 16 new positions and closed 12 in Q3 2022.
  • Acuta Capital Partners's portfolio value rose 29% quarter-over-quarter to $232M.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.